Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Investing.com -- Novo Nordisk (CSE:NOVOb) on Wednesday said it will cut about 9,000 jobs worldwide, including 5,000 in ...

These high-yielding S&P 500 stocks offer incredible, dependable yields from quality blue-chip companies you can buy and hold ...

Novo Nordisk said the overhaul resulted in one-off costs of about DKK 9 billion in 2025, including DKK 5 billion in severance ...

BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.

Despite the steep bottom-line drop, analysts tracking BioMarin stock were expecting worse. Their consensus estimate was for a ...

Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...

Erian, Allianz chief economic advisor, said in a recent interview on CNBC that we are in a “rational” AI bubble because the “promise” of the technology is huge.

Amid slow sales, BioMarin will continue to make the gene therapy commercially available in the US, Italy, and Germany while it finalizes next steps.

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

Growing concerns over the lack of adequate healthcare services and the shortage of trained medical professionals in rural Gambia took center stage at the Safe Motherhood and Hemophilia Foundation's ...